WHO Drug Information Vol. 13, No. 4, 1999
(1999; 83 pages) View the PDF document
Table of Contents
Open this folder and view contentsGeneral Policy Issues
Open this folder and view contentsReports on Individual Drugs
Open this folder and view contentsCurrent Topics
Open this folder and view contentsVaccines and Biomedicines
Close this folderRegulatory and Safety Matters
View the documentLeflunomide: pancytopenia and skin reactions
View the documentDidanosine and pancreatitis
View the documentSertraline for post-traumatic stress disorder
View the documentPemoline withdrawal following liver complications
View the documentLevetiracetam: new drug for epilepsy
View the documentMethotrexate: monitoring essential
View the documentMethotrexate: care in prescribing
View the documentGrepafloxacin withdrawal: severe cardiovascular events
View the documentReteplase incompatible with heparin
View the documentPostmarketing system to be revised
View the documentAbacavir: hypersensitivity reactions
View the documentInitiative to curb illegal sale of drugs over the Internet
View the documentUnapproved HIV test kits available on the Internet
View the documentV-King®: unapproved use of sildenafil
View the documentMiralex®: undeclared corticosteroid
View the documentRules for dietary supplements finalized
Open this folder and view contentsATC/DDD Classification
Open this folder and view contentsEssential Drugs
View the documentInternational Nonproprietary Names for Pharmaceutical Substances (INN)
View the documentSelected WHO Publications of Related Interest
 

Rules for dietary supplements finalized

United States of America — The Food and Drug Administration has published its final rule defining the types of statements that can be made concerning the effect of a dietary supplement on the structure or function of the body. This rule describes how disease claims can be distinguished from structure/function claims. Although this rule will not affect the availability of dietary supplements, it may affect whether certain claims can be made and will result in some labelling changes.

As an example, the rule precludes express and implied disease claims, but permits claims that do not relate to disease. Serious conditions such as ageing, pregnancy, and menopause will continue to be treated as diseases.

Publication of the rule is an important part of the FDA's overall dietary supplement strategy aimed at providing consumers with a high level of confidence in the safety, composition and labelling of dietary supplements.

Reference: FDA Talk Paper, T00-1, 2000.

to previous section to next section
 

Last updated: May 3, 2013